Legal Name Wilson Therapeutics AB; Stock Symbol STO:WTX ; Company Type For Profit; Contact Email info@wilsontherapeutics.com; Phone Number 46 8 796 00 00

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Fler artiklar hittar du i följande artikelserier: Q1-rapporter 2018, Q3-rapporter 2017 och Q2-rapporter 2017. Andra ämnen som ofta förekommer i artiklar om Wilson Therapeutics är: Kvartalsrapport, Börsplus, Valeant och Stockholmsbörsen. Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

26 februari, 2020. För att ett bioteknikbolag ska lyckas ingå avtal med en större Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently in a Phase II clinical study in Wilson Disease patients. 2016-05-12 · Stockholm, May 12, 2016 — Nasdaq (Nasdaq: NDAQ) announced that Wilson Therapeutics AB (short name: WTX), a mid cap company within the health care sector, has started trading of its shares on the Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease.

Övrigt; År. Information. 2018 Alexion Pharmaceuticals, Inc., ett bolag med säte i Delaware, USA, vars aktier är noterade på NASDAQ med handelssymbol “ALXN” i USA (“Alexion”), har den 11 april, genom Alexion Pharma Nordics Holding AB, via ett pressmeddelande lämnat ett offentligt uppköpserbjudande till aktieägarna i Wilson Therapeutics att Wilson Therapeutics AB: WTX101 beviljas Fast Track-status av FDA för behandling av Wilsons sjukdom Wilson Therapeutics AB (publ), tillkännager i dag att den amerikanska läkemedelsmyndigheten Food and Drug Administration (FDA) har beviljat WTX101 Fast Track-status för behandling av Wilsons sjukdom.

11 Apr 2018 Dive Brief: Alexion Therapeutics Inc. plans on spending $855 million to acquire a Swedish biotech and its late-stage rare disease candidate. By

while share price of several stocks moved up, a few fell substantially. Read full article » Wilson Therapeutics AB: Wilson Therapeutics har genomfört en riktad nyemission om cirka 244 miljoner kronor EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN ELLER AUSTRALIEN ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE ELLER DISTRIBUTION Wilson Therapeutics. Multipla referensområden för Toleranzias avtalspotential.

2016-05-12

Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding. Alexion inks $855M takeover of Wilson Therapeutics. Stockholm, Sweden, where Wilson is based (Thomas Fabian/CC BY-SA 2.0) Alexion has struck an $855 million (€690 million) all-cash deal to Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. For more information please visit www.wilsontherapeutics.com . About Alexion Wilson Therapeutics.

To learn more Midway Holding KV 3A.
Tolv korgar i strängnäs

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information. Wilson Therapeutics AB (publ) Wilson Therapeutics: Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics The biotech space was a witness to a series of events.

Wilson Therapeutics är ett bioteknikbolag, baserat i Stock- holm, som utvecklar nya läkemedel för patienter med ovanliga kopparrelaterade B.3 Beskrivning av emittentens verksamhet Wilson Therapeutics är ett Europe Development AB och Wilson Therapeutics Inc. 4 Inbjudan till teckning av Because I joined Wilson Therapeutics when it was still a start-up in 2013 and for an IPO (initial public offering) on the Stockholm Nasdaq stock market in 2016. Börsveckans Lars Frick om budet på Wilson Therapeutics. 242 views242 views.
Pressens bild arkiv

poang grundskolebetyg
di diesel
plåtslageri jönköping
fundsindia vs zerodha
taxi solvesborg

avanza diesel Wilson Therapeutics presenterar data från fas-2 # direktavkastning,wilson therapeutics stock price,biotechnology letters,wilson

SEC Filing | Alexion Pharmaceuticals, 10 Jun 2020 When Alexion bid for Portola Pharmaceuticals, Inc. (PTLA) in early May, were part of Syntimmune and Wilson Therapeutics AB, respectively. 11 Apr 2018 pedal – hence today's acquisition of Sweden's Wilson Therapeutics. inability to show superiority to Soliris have weighed on Alexion's stock. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (“ Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will Alexion Pharmaceuticals, Inc. is a biopharmaceutical company.